Supporting our observation of ovarian lineage specificity, CRL4 has been identified as a potential therapeutic target in ovarian cancers,38, 67 and these screening efforts underscore the promise of developing pharmacological inhibitors of E3 ligase complexes for cancer treatment. The gene discussed is IL17RB; the disease is ovarian cancer.